Aflac Incorporated generated $17.4 billion in total revenues for the fiscal year 2024, operating as the dominant provider of supplemental health insurance in the United States and the leading seller of cancer insurance in Japan. The company has fundamentally restructured its operations through aggressive digital transformation and AI integration, reducing administrative costs while maintaining a combined ratio below 95% and generating massive free cash flow to return to shareholders.
Aflac Incorporated: Key Facts
- Founded: 1955 in Columbus, Georgia by John, Paul, and Bill Amos.
- Headquarters: Columbus, Georgia, United States.
- CEO: Daniel M. Massey (CEO since 2022).
- FY2024 Revenue: $17.4 billion, driven by robust net investment income and stable premium growth.
- Employees: Approximately 11,500 globally.
- Primary Product: Supplemental health insurance (accident, critical illness, hospital indemnity) and cancer insurance.
How Does Aflac Make Money?
Aflac generates its revenue primarily through net earned premiums from its supplemental health and life insurance products, which pay cash benefits directly to policyholders to cover out-of-pocket medical expenses and non-medical costs. The company's business model is uniquely bifurcated, with its Japanese subsidiary generating the majority of its net earned premiums, often accounting for over 60% of the total premium volume. In the United States, Aflac operates as the dominant provider of supplemental health insurance, offering products designed to fill the gaps left by high-deductible health plans. When a policyholder experiences a covered event, Aflac pays a cash benefit directly to the individual, rather than paying a healthcare provider. Beyond premium collection, Aflac's business model is heavily dependent on its investment operations. The company collects billions in premiums upfront and pays out claims over time, creating a massive float that is invested primarily in fixed-income securities. The net investment income generated from this $160 billion portfolio is a critical component of Aflac's profitability, often accounting for 20% to 30% of the company's total pre-tax earnings. In a higher-interest-rate environment, Aflac is able to reinvest maturing bonds and new premium cash flows at higher yields, gradually increasing the overall yield of its portfolio and expanding its net investment income margin.
Who Founded Aflac and When?
Aflac was founded in 1955 by three brothers: John Amos, Paul Amos, and Bill Amos, in Columbus, Georgia. They started the company, originally named the American Family Life Assurance Company, with the specific mission of offering cancer insurance policies that would provide a cash benefit directly to the policyholder upon diagnosis. At the time, major medical insurance was in its infancy, and most policies excluded cancer treatment entirely, leaving families financially ruined when a loved one was diagnosed with the disease. The Amos brothers identified this massive gap in the American insurance market and dedicated their lives to providing financial protection against the devastating costs of critical illness. The early years were defined by relentless struggle and widespread rejection, as cancer was a taboo subject and most people did not want to think about the possibility of getting the disease. However, the brothers' persistence and their revolutionary pivot to worksite marketing in the 1960s ultimately provided the breakthrough that allowed Aflac to scale nationally and become the dominant force in the supplemental insurance industry.
What Is Aflac's Competitive Advantage?
Aflac's single most unreplicable moat is its proprietary worksite distribution network in the United States, combined with its absolute dominance in the Japanese cancer insurance market, creating a dual-engine growth model that competitors cannot easily replicate. In the US, Aflac's network of over 30,000 independent agents, who sell products directly to employees in the workplace, represents a massive, highly efficient customer acquisition channel that has been built over seven decades. This worksite model benefits from the implicit endorsement of the employer, which drives high participation rates and low policy lapse rates, and it results in a customer acquisition cost that is a fraction of the direct-to-consumer or broker-driven models utilized by competitors. Once an employer agrees to host Aflac agents, the switching costs for the employer to bring in a competitor are incredibly high, as the employer has already integrated Aflac into its benefits communication and enrollment processes. In Japan, Aflac's competitive advantage is rooted in its first-mover status and its unparalleled brand recognition in the cancer insurance segment. Aflac Japan pioneered the concept of cash-benefit cancer insurance in the 1970s, and over the past five decades, it has built a massive, highly profitable book of business that holds over a 50% market share in the segment. The Japanese consumer deeply trusts the Aflac brand for cancer protection, and the company's extensive network of agency shops and direct sales agents creates a level of market penetration and customer service that is virtually impossible for new entrants to match.
How Has Aflac's Revenue Grown Over Time?
Aflac's revenue has grown steadily over the decades, driven by its expansion into Japan, the introduction of the Aflac Duck campaign, and the secular shift toward high-deductible health plans in the US. For the fiscal year 2024, the company reported total revenues of $17.4 billion, representing a strong performance driven by robust net investment income and stable premium growth across its US and Japanese segments. The company's net earnings for the year reached approximately $4.5 billion, translating to diluted earnings per share of roughly $8.50, a testament to the company's disciplined expense management and its aggressive share repurchase program. Net earned premiums, which totaled approximately $12.5 billion in 2024, were driven by strong renewal retention rates in both the US and Japan. Net investment income generated approximately $5.5 billion in 2024, a significant increase from previous years as the company successfully reinvested maturing bonds and new premium cash flows into higher-yielding fixed-income securities in the sustained higher-interest-rate environment. The yield on Aflac's $160 billion investment portfolio increased by approximately 30 basis points year-over-year, reaching roughly 4.8%, providing a substantial boost to the company's bottom line. This consistent revenue growth, combined with disciplined capital allocation, has allowed Aflac to return over 100% of its adjusted free cash flow to shareholders through dividends and share repurchases, driving a 40% reduction in its outstanding share count over the past decade.
Aflac Business Model Explained
Aflac's business model is built on the spread between the premiums collected from millions of policyholders and the claims paid out, supplemented by the substantial investment income generated by deploying those premiums into a highly diversified, fixed-income-heavy portfolio. The company's supplemental products, which include accident, critical illness, hospital indemnity, and short-term disability insurance, pay cash benefits directly to the policyholder, allowing them to cover out-of-pocket medical expenses or non-medical costs like rent and groceries. This value proposition has become increasingly critical as high-deductible health plans continue to shift financial risk from employers to individual employees. The US distribution model is centered around worksite marketing, where Aflac utilizes a network of over 30,000 independent agents to present their products directly to employees in the workplace. This worksite model is incredibly efficient, resulting in a customer acquisition cost that is a fraction of the direct-to-consumer or broker-driven models utilized by competitors. In Japan, Aflac's business model is fundamentally different, operating as a top-tier life insurer with a dominant position in the cancer insurance segment. The Japanese national health insurance system covers approximately 70% of medical costs, but patients are still responsible for the remaining 30% out-of-pocket, and cancer treatments often require long-term care, experimental therapies, and lost income that the national system does not fully cover. Aflac Japan pioneered the concept of cash-benefit cancer insurance in the 1970s, offering policies that pay a lump sum or daily cash benefit directly to the policyholder upon diagnosis or hospitalization. This product resonated deeply with the Japanese consumer, allowing Aflac to capture over a 50% market share in the cancer insurance segment and build a massive, highly profitable book of business that generates over $10 billion in annual premiums.
Aflac Key Acquisitions
Aflac has executed several strategic acquisitions to expand its geographic footprint and product offerings, most notably the 2010 acquisition of ALICO Japan from AIG for approximately $1.5 billion. This deal instantly established Aflac's absolute dominance in the Japanese life insurance market, adding over $3 billion in annual premiums to Aflac's top line and significantly expanding its market share. The acquisition provided Aflac with a massive, diversified book of business that included life, medical, and cancer insurance products, allowing the company to cross-sell its products to ALICO's existing customer base and achieve significant cost synergies. The integration was highly successful, making Aflac Japan the undisputed leader in the Japanese insurance market and providing a stable cash flow engine that funds the company's aggressive capital return strategy. In 1999, Aflac acquired Federal Insurance Company to expand its US product portfolio and distribution capabilities, particularly in the group insurance and benefits market. This acquisition provided Aflac with additional scale in the US market and enhanced its ability to offer a comprehensive suite of supplemental and group benefits to large national accounts, strengthening its position as the leading provider of supplemental insurance in the United States.
What Are the Biggest Risks Facing Aflac?
The most immediate and persistent threat to Aflac's margin expansion and long-term growth is the profound demographic crisis in Japan, where the company generates the majority of its net earned premiums. Japan is experiencing a rapidly aging population and a shrinking workforce, a structural headwind that directly impacts the life and cancer insurance market by reducing the pool of potential new policyholders and increasing the frequency of claims as the existing policyholder base ages. While the aging population drives demand for cancer insurance, it also means that the book of business is maturing, and the company must constantly innovate to cross-sell new products, such as medical and nursing care insurance, to its existing elderly customer base to offset the natural runoff of older policies. Concurrently, Aflac faces significant interest rate risk across its global investment portfolio, which totals over $160 billion. While the recent higher-interest-rate environment has allowed Aflac to increase the yield on its new investments, a sudden and sustained drop in interest rates would force the company to reinvest maturing bonds at lower yields, compressing its net investment income and directly impacting its bottom line. In the United States, the supplemental insurance market is facing increasing competition from major medical insurers and large brokers who are bundling supplemental products with their core health plans, threatening Aflac's dominant market share. Companies like UnitedHealth Group, Aetna, and Cigna are leveraging their massive scale and existing relationships with employers to offer their own branded supplemental products, often at lower prices, forcing Aflac to defend its market position through aggressive pricing and enhanced product features.
Bottom Line
Aflac Incorporated is undeniably growing, having generated $17.4 billion in total revenues in 2024 while maintaining a combined ratio below 95% and generating massive free cash flow. The company has successfully navigated the complex bifurcation between the US worksite market and the Japanese direct-to-consumer market, creating a dual-engine growth model that provides unparalleled financial resilience. As it continues to invest in AI-driven operational efficiency and expand its voluntary benefits portfolio, Aflac is well-positioned to maintain its leadership position and deliver attractive returns to its shareholders for decades to come.
